Lickliter JD - Search Results

1

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.

Gan HK, Millward M, Hua Y, Qi C, Sai Y, Su W, Wang J, Zhang L, Frigault MM, Morgan S, Yang L, Lickliter JD. Gan HK, et al. Among authors: lickliter jd. Clin Cancer Res. 2019 Aug 15;25(16):4924-4932. doi: 10.1158/1078-0432.CCR-18-1189. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952639 Clinical Trial.

2

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.

Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H, Rosenthal MA. Whittle JR, et al. Among authors: lickliter jd. J Clin Neurosci. 2015 Dec;22(12):1889-94. doi: 10.1016/j.jocn.2015.06.005. Epub 2015 Aug 13. J Clin Neurosci. 2015. PMID: 26279503 Clinical Trial.

3

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.

Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y, Brown MP, Millward M. Dredge K, et al. Among authors: lickliter jd. Br J Cancer. 2018 Apr;118(8):1035-1041. doi: 10.1038/s41416-018-0006-0. Epub 2018 Mar 13. Br J Cancer. 2018. PMID: 29531325 Free PMC article. Clinical Trial.

4

First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.

Okour M, Gress A, Zhu X, Rieman D, Lickliter JD, Brigandi RA. Okour M, et al. Among authors: lickliter jd. Clin Pharmacol Drug Dev. 2019 Nov;8(8):1088-1099. doi: 10.1002/cpdd.691. Epub 2019 Apr 5. Clin Pharmacol Drug Dev. 2019. PMID: 30950565 Clinical Trial.

5

Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).

Panizza BJ, de Souza P, Cooper A, Roohullah A, Karapetis CS, Lickliter JD. Panizza BJ, et al. Among authors: lickliter jd. EBioMedicine. 2019 Dec;50:433-441. doi: 10.1016/j.ebiom.2019.11.037. Epub 2019 Dec 3. EBioMedicine. 2019. PMID: 31810818 Free PMC article. Clinical Trial.

6

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.

Kato H, de Souza P, Kim SW, Lickliter JD, Naito Y, Park K, Kumar S, Mugundu GM, Bang YJ. Kato H, et al. Among authors: lickliter jd. Target Oncol. 2020 Feb;15(1):75-84. doi: 10.1007/s11523-020-00701-5. Target Oncol. 2020. PMID: 32034630 Free PMC article. Clinical Trial.

7

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.

Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T. Lickliter JD, et al. Drug Des Devel Ther. 2020 Mar 18;14:1177-1189. doi: 10.2147/DDDT.S243787. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32256049 Free PMC article. Clinical Trial.

8

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.

Gan HK, Millward M, Jalving M, Garrido-Laguna I, Lickliter JD, Schellens JHM, Lolkema MP, Van Herpen CLM, Hug B, Tang L, O'Connor-Semmes R, Gagnon R, Ellis C, Ganji G, Matheny C, Drilon A. Gan HK, et al. Among authors: lickliter jd. Oncologist. 2021 Oct;26(10):e1844-e1853. doi: 10.1002/onco.13860. Epub 2021 Jul 21. Oncologist. 2021. PMID: 34132450 Free PMC article. Clinical Trial.

9

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.

Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Lickliter JD, et al. Br J Cancer. 2022 Mar;126(4):576-585. doi: 10.1038/s41416-021-01632-2. Epub 2021 Nov 18. Br J Cancer. 2022. PMID: 34795408 Free PMC article. Clinical Trial.

10

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.

Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Lickliter JD, et al. Br J Cancer. 2022 Feb;126(2):310. doi: 10.1038/s41416-021-01671-9. Br J Cancer. 2022. PMID: 34931042 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page